博彩网址平台www.99cx.vip)是一个开放皇冠体育网址代理APP下载、皇冠体育网址会员APP下载、皇冠体育网址线路APP下载、皇冠体育网址登录APP下载的官方平台。博彩网址平台上博彩网址平台会员登录线路、博彩网址平台代理网址更新最快。博彩网址平台开放皇冠官方会员注册、皇冠官方代理开户等业务。

MIDF Research said while it was positive on the endeavour, the feasibility of the partnership and strategies would not be visible until at least next year.

PETALING JAYA: Pharmaniaga Bhd’s new venture involving the production of halal medicines is expected to bear fruit earliest, by next year.

MIDF Research said while it was positive on the endeavour, the feasibility of the partnership and strategies would not be visible until at least next year.

“We make no changes to our earnings estimates for financial year 2022 (FY22) to FY23, thus maintaining our target price at 91 sen for Pharmaniaga.

“The development of the halal anti-coagulant would not be finalised until approval by the National Pharmaceutical Regulatory Agency by 2024, with the risk of a fallout still an immediate possibility,” it said in a report.

Pharmaniaga said last week that it would commercialise Malaysia’s halal ovine (sheep and goat) anti-coagulant (blood clot thinner) drug in Malaysia by 2024.

The venture is a collaboration with China’s Ronnsi Pharma Co Ltd.

MIDF in its report noted that Covid-19 had added to the need for anti-coagulants in a bid to prevent severe complications from thromboembolism.

“Additionally, ischaemic heart diseases had seen a significant increase by 24% from 2015 to 2020, adding to the need for anti-blood clot agent to ease heart surgery and minimise complication,” it said.

,

新2最新网址www.hg108.vip)实时更新发布最新最快最有效的新2网址和新2最新网址,包括新2手机网址,新2备用网址,皇冠最新网址,新2足球网址,新2网址大全。

,

It also noted that the anti-coagulant market is expected to reach eight million dosages by 2026. There are big opportunities in halal market, it said.

“Anti-coagulants are used for invasive surgeries, as well as in preventive treatment for cardiovascular and cerebrovascular diseases.

“As most anti-coagulants in the market currently is derived from swine, the demand for halal anti-coagulants is expected to rise.”

It said the venture will position Pharmaniaga as the exclusive registration holder, distributor and manufacturer, with Ronnsi as the patent owner and developer.

It will also contribute to Malaysia’s potential as the first distributor and manufacturer of halal blood anti-coagulants, MIDF said.

In its report, MIDF pointed out that Ronnsi was founded in 2012 and is a pharma company focusing on complex drug research and development, with its main products being Heparin, Enoxaparin and Dalteparin salts.

“Ronnsi is the first developer of non-porcine-based enoxaparin, which has passed all approvals and is currently commercialised globally as an ovine-based anti-coagulant.

“Through this expertise, the group has collaborated with various international companies including from Indonesia, Pakistan, the United States and Italy.”

Still, there are threats to this partnership including pricing pressures and increased competition, MIDF said in its risk analysis.

环球UG声明:该文看法仅代表作者自己,与本平台无关。转载请注明:新2最新网址:Big halal medicine market for Pharmaniaga
发布评论

分享到:

Gmaing(www.aLLbet8.vip):Malaysian ringgit, Thai baht hit by safety flows, growth woes
你是第一个吃螃蟹的人
发表评论

◎欢迎参与讨论,请在这里发表您的看法、交流您的观点。